{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:13:26Z","timestamp":1787022806258,"version":"build-2736575974"},"reference-count":31,"publisher":"Bioscientifica","issue":"4","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ec.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to describe in a real-life setting the treatment burden and adherence and quality of life (QOL) of children treated with daily injections of growth hormone and their relationship with treatment duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This non-interventional, multicenter, cross-sectional French study involved children aged 3\u201317 years treated with daily growth hormone injections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Based on a recent validated dyad questionnaire, the mean overall life interference total score (100\u2009=\u2009most interference) was described, with treatment adherence and QOL, using the Quality of Life of Short Stature Youth questionnaire (100\u2009=\u2009best). All analyses were performed according to treatment duration prior to inclusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 275\/277 analyzed children, 166 (60.4%) had only growth hormone deficiency (GHD). In the GHD group, the mean age was 11.7 \u00b1 3.2 years; median treatment duration was 3.3 years (interquartile range 1.8\u20136.4). The mean overall life interference total score was 27.7 \u00b1 20.7 (95% CI (24.2; 31.2)), with non-significant correlation with treatment duration (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.1925). Treatment adherence was good (95.0% of children reported receiving &gt;80% of planned injections over the last month); it slightly decreased with treatment duration (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0364). Children\u2019s overall QOL was good (81.5 \u00b1 16.6 and 77.6 \u00b1 18.7 according to children and parents, respectively), but subscores of the coping and treatment impact domains were &lt;50. Similar results were observed in all patients independently of the condition requiring treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This real-life French cohort confirms the treatment burden of daily growth hormone injections, as previously reported in an interventional study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/ec-22-0464","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T06:15:02Z","timestamp":1677824102000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":16,"title":["Treatment burden, adherence, and quality of life in children with daily GH treatment in France"],"prefix":"10.1530","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6332-4243","authenticated-orcid":true,"given":"R\u00e9gis","family":"Coutant","sequence":"first","affiliation":[{"name":"Department of Pediatric Endocrinology and Diabetology, Reference Center for Rare Pituiatry Diseases, University Hospital of Angers, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0363-7862","authenticated-orcid":true,"given":"Maith\u00e9","family":"Tauber","sequence":"additional","affiliation":[{"name":"Reference Center for the Prader-Willi syndrome and other rare obesities with feeding disorders (PRADORT), Children Hospital, CHU Toulouse, Toulouse, France"},{"name":"Pediatric team of the Clinical Investigation Center 9302\/INSERM, Hospital of Children, Toulouse, France"},{"name":"Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051 - Universit\u00e9 Toulouse III, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8618-7213","authenticated-orcid":true,"given":"B\u00e9atrice","family":"Demaret","sequence":"additional","affiliation":[{"name":"GRANDIR - French Growth Disorders Association, Asni\u00e8res-sur-Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6205-1941","authenticated-orcid":true,"given":"Robin","family":"Henocque","sequence":"additional","affiliation":[{"name":"Pfizer France, Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Brault","sequence":"additional","affiliation":[{"name":"Pfizer France, Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-6630","authenticated-orcid":true,"given":"Fran\u00e7ois","family":"Montestruc","sequence":"additional","affiliation":[{"name":"eXYSTAT, Malakoff, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8361-5809","authenticated-orcid":true,"given":"Olivier","family":"Chassany","sequence":"additional","affiliation":[{"name":"Health Economics Clinical Trial Unit (URC-ECO), Hospital of Hotel-Dieu, AP-HP, Paris, France"},{"name":"Patient-Reported Outcomes Unit (PROQOL), UMR 1123, University Paris Cit\u00e9, INSERM, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2639-352X","authenticated-orcid":true,"given":"Michel","family":"Polak","sequence":"additional","affiliation":[{"name":"H\u00f4pital Universitaire Necker Enfants Malades, Pediatric Endocrinology, Gynecology and Diabetology, Imagine Institute, INSERM U1163, Cochin Institute, INSERM U1016, Centre de r\u00e9f\u00e9rence des pathologies endocriniennes rares de la croissance et du d\u00e9veloppement, Universit\u00e9 de Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"_","family":"_","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Pharmacological Reports","first-page":"500","article-title":"Growth hormone therapy in children and adults","volume":"59","author":"Krysiak","year":"2007","unstructured":"Krysiak RGdula-Dymek ABednarska-Czerwi\u0144ska A & Okopie\u0144 B. Growth hormone therapy in children and adults. Pharmacological Reports200759500\u2013516.18048950"},{"issue":"Supplement 1","key":"bib2","series-title":"European Journal of Endocrinology","first-page":"S97","article-title":"Adult GH deficiency throughout lifetime","volume":"161","author":"Thomas","year":"2009","unstructured":"Thomas JD & Monson JP. Adult GH deficiency throughout lifetime. European Journal of Endocrinology2009161(Supplement 1) S97\u2013S106. (https:\/\/doi.org\/10.1530\/EJE-09-0258)19684058"},{"key":"bib3","series-title":"European Journal of Endocrinology","first-page":"695","article-title":"Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia","volume":"157","author":"Ho","year":"2007","unstructured":"Ho KK & GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. European Journal of Endocrinology2007157695\u2013700. (https:\/\/doi.org\/10.1530\/EJE-07-0631)"},{"key":"bib4","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"4210","article-title":"Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop","volume":"93","author":"Cohen","year":"2008","unstructured":"Cohen PRogol ADDeal CLSaenger PReiter EORoss JLChernausek SDSavage MOWit JM & ISS Consensus WorkshopParticipants. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. Journal of Clinical Endocrinology and Metabolism2008934210\u20134217. (https:\/\/doi.org\/10.1210\/jc.2008-0509)"},{"key":"bib5","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"2103","article-title":"Improved general and height-specific quality of life in children with short stature after 1 year on growth hormone","volume":"104","author":"Gonz\u00e1lez Brice\u00f1o","year":"2019","unstructured":"Gonz\u00e1lez Brice\u00f1o LGViaud MBeltrand JFlechtner IDassa YSamara-Boustani DThalassinos CPauwels CBusiah KPinto G, Improved general and height-specific quality of life in children with short stature after 1 year on growth hormone. Journal of Clinical Endocrinology and Metabolism20191042103\u20132111. (https:\/\/doi.org\/10.1210\/jc.2018-02523)30649493"},{"key":"bib6","series-title":"Frontiers in Pediatrics","article-title":"Quality of life of short-statured children born small for gestational age or idiopathic growth hormone deficiency within 1 year of growth hormone treatment","volume":"2019","author":"Quitann","unstructured":"Quitann JBloemeke JSilva NBullinger MWitt SAkkurt IDunstheimer DVogel CB\u00f6ttcher VKuhnle Krahl U, Quality of life of short-statured children born small for gestational age or idiopathic growth hormone deficiency within 1 year of growth hormone treatment. Frontiers in Pediatrics2019 164. (https:\/\/doi.org\/10.3389\/fped.2019.00164)"},{"key":"bib7","series-title":"Clinical Pharmacology: Advances and Applications","first-page":"111","article-title":"Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review","volume":"2","author":"Reh","year":"2010","unstructured":"Reh CS & Geffner ME. Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review. Clinical Pharmacology: Advances and Applications20102111\u2013122. (https:\/\/doi.org\/10.2147\/CPAA.S6525)22291494"},{"key":"bib8","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"1728","article-title":"Long-term safety of growth hormone treatment in childhood: two large observational studies: NordiNet IOS and ANSWER","volume":"106","author":"S\u00e4vendahl","year":"2021","unstructured":"S\u00e4vendahl LPolak MBackeljauw PBlair JCMiller BSRohrer TRHokken-Koelega APietropoli AKelepouris N & Ross J. Long-term safety of growth hormone treatment in childhood: two large observational studies: NordiNet IOS and ANSWER. Journal of Clinical Endocrinology and Metabolism20211061728\u20131741. (https:\/\/doi.org\/10.1210\/clinem\/dgab080)33571362"},{"key":"bib9","series-title":"Hormone Research in Paediatrics","first-page":"189","article-title":"Understanding the growth hormone therapy adherence paradigm: a systematic review","volume":"79","author":"Fisher","year":"2013","unstructured":"Fisher BG & Acerini CL. Understanding the growth hormone therapy adherence paradigm: a systematic review. Hormone Research in Paediatrics201379189\u2013196. (https:\/\/doi.org\/10.1159\/000350251)23635797"},{"key":"bib10","series-title":"Endocrine Connections","first-page":"914","article-title":"Adherence and long-term growth outcomes: results from the easypod\u2122 connect observational study (ECOS) in paediatric patients with growth disorders","volume":"7","author":"Koledova","year":"2018","unstructured":"Koledova EStoyanov GOvbude L & Davies PSW. Adherence and long-term growth outcomes: results from the easypod\u2122 connect observational study (ECOS) in paediatric patients with growth disorders. Endocrine Connections20187914\u2013923. (https:\/\/doi.org\/10.1530\/EC-18-0172)29976785"},{"key":"bib11","series-title":"Endocrine Practice","first-page":"143","article-title":"Compliance and persistence in pediatric and adult patients receiving growth hormone therapy","volume":"14","author":"Rosenfeld","year":"2008","unstructured":"Rosenfeld RG & Bakker B. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocrine Practice200814143\u2013154. (https:\/\/doi.org\/10.4158\/EP.14.2.143)18308651"},{"key":"bib12","series-title":"PLoS One","article-title":"Experience of switching from a daily to a less frequent administration of injection treatments","volume":"17","author":"Loftus","year":"2022","unstructured":"Loftus JYaworsky ARoland CLTurner-Bowker DMcLafferty MSu S & Lamoureux RE. Experience of switching from a daily to a less frequent administration of injection treatments. PLoS One202217 e0278293. (https:\/\/doi.org\/10.1371\/journal.pone.0278293)36449502"},{"issue":"Supplement 1","key":"bib13","series-title":"Journal of the Endocrine Society","first-page":"OR10","article-title":"OR10-06 Somatrogon growth in the treatment of pediatric growth hormone deficiency: results of the pivotal pediatric phase 3 clinical trial","volume":"4","author":"Deal","year":"2020","unstructured":"Deal CLPastrack ASilverman LAValluri SRWajnrajch MP & Cara JF. OR10-06 Somatrogon growth in the treatment of pediatric growth hormone deficiency: results of the pivotal pediatric phase 3 clinical trial. Journal of the Endocrine Society20204(Supplement 1) OR10\u2013OR06. (https:\/\/doi.org\/10.1210\/jendso\/bvaa046.1279)"},{"key":"bib14","series-title":"Hormone Research in Paediatrics","article-title":"Long-acting growth hormone preparations and their use in children with growth hormone deficiency","author":"Pampanini","year":"2022","unstructured":"Pampanini VDeodati AInzaghi E & Cianfarani S. Long-acting growth hormone preparations and their use in children with growth hormone deficiency. Hormone Research in Paediatrics2022. (https:\/\/doi.org\/10.1159\/000523791)35220308"},{"key":"bib15","article-title":"Summary of product characteristics","author":"European Medicines Agency","unstructured":"European Medicines Agency Ngenla: Summary of product characteristics. (available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ngenla-epar-product-information_en.pdf)."},{"key":"bib16","series-title":"Patient","first-page":"289","article-title":"Development and psychometric evaluation of the Life Interference Questionnaire for growth hormone deficiency (LIQGHD) to assess growth hormone injection burden in children and adults","volume":"13","author":"Turner-Bowker","year":"2020","unstructured":"Turner-Bowker DMYaworsky APalladino ALamoureux REKelly MLove EPleil AMShields A & Loftus J. Development and psychometric evaluation of the Life Interference Questionnaire for growth hormone deficiency (LIQGHD) to assess growth hormone injection burden in children and adults. Patient202013289\u2013306. (https:\/\/doi.org\/10.1007\/s40271-019-00405-7)31956960"},{"key":"bib17","series-title":"Journal of the Endocrine Society","article-title":"Treatment burden of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a randomized study","volume":"6","author":"Maniatis","year":"2022","unstructured":"Maniatis AKCarakushansky MGalcheva SPrakasam GFox LADankovcikova ALoftus JPalladino AAde Los Angeles Resa MTurich Taylor C, Treatment burden of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a randomized study. Journal of the Endocrine Society20226 bvac117. (https:\/\/doi.org\/10.1210\/jendso\/bvac117)36101713"},{"key":"bib18","series-title":"Guide Aide \u00e0 l\u2019Utilisation de Questionnaires Patients de Mesure des R\u00e9sultats de Soins (Proms) pour Am\u00e9liorer la Pratique Clinique Courante - Approche Th\u00e9orique et Crit\u00e8res Op\u00e9rationnels","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Guide Aide \u00e0 l\u2019Utilisation de Questionnaires Patients de Mesure des R\u00e9sultats de Soins (Proms) pour Am\u00e9liorer la Pratique Clinique Courante - Approche Th\u00e9orique et Crit\u00e8res Op\u00e9rationnels. (available at: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-07\/iqss_guide_proms_general_2021.pdf)"},{"key":"bib19","series-title":"Rapport Qualit\u00e9 des Soins Per\u00e7ue par le Patient \u2013 Indicateurs Proms et PREMs Panorama d\u2019Exp\u00e9riences \u00c9trang\u00e8res et Principaux Enseignements","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Rapport Qualit\u00e9 des Soins Per\u00e7ue par le Patient \u2013 Indicateurs Proms et PREMs Panorama d\u2019Exp\u00e9riences \u00c9trang\u00e8res et Principaux Enseignements. (available at: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-07\/rapport_panorama_proms_prems_2021.pdf)"},{"key":"bib20","article-title":"Regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products - Scientific guideline","unstructured":"European Medicines Agency. Regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products - Scientific guideline. (available at: https:\/\/www.ema.europa.eu\/en\/regulatory-guidance-use-health-related-quality-life-hrql-measures-evaluation-medicinal-products)"},{"key":"bib21","article-title":"Guidance document. Patient-Reported Outcome Measures: use in medical product development to support labeling claims","unstructured":"Food and Drug Administration. Guidance document. Patient-Reported Outcome Measures: use in medical product development to support labeling claims. (available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims)"},{"key":"bib22","series-title":"Health and Quality of Life Outcomes","article-title":"Assessing the quality of life of health-referred children and adolescents with short stature: development and psychometric testing of the QoLISSY instrument","volume":"11","author":"Bullinger","year":"2013","unstructured":"Bullinger MQuitmann JPower MHerdman MMimoun EDeBusk KFeigerlova ELunde CDellenmark-Blom MSanz D, Assessing the quality of life of health-referred children and adolescents with short stature: development and psychometric testing of the QoLISSY instrument. Health and Quality of Life Outcomes201311 76. (https:\/\/doi.org\/10.1186\/1477-7525-11-76)23648112"},{"key":"bib23","series-title":"Medical Care","first-page":"126","article-title":"The PedsQL: measurement model for the pediatric quality of life inventory","volume":"37","author":"Varni","year":"1999","unstructured":"Varni JWSeid M & Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Medical Care199937126\u2013139. (https:\/\/doi.org\/10.1097\/00005650-199902000-00003)10024117"},{"key":"bib24","series-title":"PLoS One","article-title":"Non-compliance with growth hormone treatment in children is common and impairs linear growth","volume":"6","author":"Cutfield","year":"2011","unstructured":"Cutfield WSDerraik JGGunn AJReid KDelany TRobinson E & Hofman PL. Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS One20116 e16223. (https:\/\/doi.org\/10.1371\/journal.pone.0016223)21305004"},{"key":"bib25","series-title":"Endocrine Practice","first-page":"929","article-title":"Prevalence and correlates of adherence in children and adolescents treated with growth hormone: a multicenter Italian study","volume":"23","author":"Bagnasco","year":"2017","unstructured":"Bagnasco FDi Iorgi NRoveda AGallizia AHaupt RMaghnie M & Adherence Investigators Group. Prevalence and correlates of adherence in children and adolescents treated with growth hormone: a multicenter Italian study. Endocrine Practice201723929\u2013941. (https:\/\/doi.org\/10.4158\/EP171786.OR)28614005"},{"key":"bib26","series-title":"Growth Hormone and IGF Research","first-page":"1","article-title":"Long-term adherence to growth hormone therapy in a large health maintenance organization cohort","volume":"44","author":"Farfel","year":"2019","unstructured":"Farfel AShalitin SMorag N & Meyerovitch J. Long-term adherence to growth hormone therapy in a large health maintenance organization cohort. Growth Hormone and IGF Research2019441\u20135. (https:\/\/doi.org\/10.1016\/j.ghir.2018.10.004)"},{"key":"bib27","series-title":"Clinical Therapeutics","first-page":"307","article-title":"Observations of nonadherence to recombinant human growth hormone therapy in clinical practice","volume":"30","author":"Haverkamp","year":"2008","unstructured":"Haverkamp FJohansson LDumas HLangham STauber MVeimo D & Chiarelli F. Observations of nonadherence to recombinant human growth hormone therapy in clinical practice. Clinical Therapeutics200830307\u2013316. (https:\/\/doi.org\/10.1016\/j.clinthera.2008.02.017)18343269"},{"key":"bib28","series-title":"Italian Journal of Pediatrics","article-title":"Improvement of treatment adherence with growth hormone by easypod\u2122 device: experience of an Italian centre","volume":"44","author":"Maggio","year":"2018","unstructured":"Maggio MCVergara BPorcelli P & Corsello G. Improvement of treatment adherence with growth hormone by easypod\u2122 device: experience of an Italian centre. Italian Journal of Pediatrics201844 113. (https:\/\/doi.org\/10.1186\/s13052-018-0548-z)30261918"},{"key":"bib29","series-title":"Health and Quality of Life Outcomes","article-title":"Explaining parent-child (dis)agreement in generic and short stature-specific health-related quality of life reports: do family and social relationships matter?","volume":"14","author":"Quitmann","year":"2016","unstructured":"Quitmann JRohenkohl ASommer RBullinger M & Silva N. Explaining parent-child (dis)agreement in generic and short stature-specific health-related quality of life reports: do family and social relationships matter?Health and Quality of Life Outcomes201614 150. (https:\/\/doi.org\/10.1186\/s12955-016-0553-0)27769269"},{"key":"bib30","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"2103","article-title":"Improved general and height-specific quality of life in children with short stature after 1 year on growth hormone","volume":"104","author":"Gonz\u00e1lez Brice\u00f1o","year":"2019","unstructured":"Gonz\u00e1lez Brice\u00f1o LGViaud MBeltrand JFlechtner IDassa YSamara-Boustani DThalassinos CPauwels CBusiah KPinto G, Improved general and height-specific quality of life in children with short stature after 1 year on growth hormone. Journal of Clinical Endocrinology and Metabolism20191042103\u20132111. (https:\/\/doi.org\/10.1210\/jc.2018-02523)30649493"},{"key":"bib31","series-title":"Patient Prefer Adherence","first-page":"781","article-title":"Factors driving patient preferences for growth hormone deficiency (GHD) injection regimen and injection device features: A discrete choice experiment","volume":"14","author":"McNamara","year":"2020","unstructured":"McNamara MTurner-Bowker DMWesthead HYaworsky APalladino AGross HPleil A & Loftus J. Factors driving patient preferences for growth hormone deficiency (GHD) injection regimen and injection device features: A discrete choice experiment. Patient Prefer Adherence202014781\u2013793. (https:\/\/doi.org\/10.2147\/PPA.S239196)32431492"}],"container-title":["Endocrine Connections"],"original-title":[],"link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/12\/4\/EC-22-0464.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/12\/4\/EC-22-0464.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/12\/4\/EC-22-0464.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:46:00Z","timestamp":1784555160000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/ec\/article\/1136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":31,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1530\/ec-22-0464","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]}}}